Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

48 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Re-irradiation for recurrent glioblastoma: a pattern of care analysis.
Rogers S, Gross M, Ermis E, Cosgun G, Baumert BG, Mader T, Schroeder C, Lomax N, Alonso S, Ademaj A, Lazeroms T, Lee SY, Mayinger M, Mamot C, Schwyzer L, Schubert GA, Riesterer O. Rogers S, et al. Among authors: mamot c. BMC Neurol. 2024 Nov 26;24(1):462. doi: 10.1186/s12883-024-03954-z. BMC Neurol. 2024. PMID: 39587462 Free PMC article.
Differential Efficacy From the Addition of Bortezomib to R-CHOP in Diffuse Large B-Cell Lymphoma According to the Molecular Subgroup in the REMoDL-B Study With a 5-Year Follow-Up.
Davies AJ, Barrans S, Stanton L, Caddy J, Wilding S, Saunders G, Mamot C, Novak U, McMillan A, Fields P, Collins GP, Stephens R, Cucco F, Sha C, van Hoppe M, Tooze R, Davies JR, Griffiths G, Schuh A, Burton C, Westhead DR, Du MQ, Johnson PWM. Davies AJ, et al. Among authors: mamot c. J Clin Oncol. 2023 May 20;41(15):2718-2723. doi: 10.1200/JCO.23.00033. Epub 2023 Mar 27. J Clin Oncol. 2023. PMID: 36972491 Free PMC article. Clinical Trial.
A multicenter phase II trial of anti-EGFR-immunoliposomes loaded with doxorubicin in patients with advanced triple negative breast cancer.
Mamot C, Wicki A, Hasler-Strub U, Riniker S, Li Q, Holer L, Bärtschi D, Zaman K, von Moos R, Dedes KJ, Boos LA, Novak U, Bodmer A, Ritschard R, Obermann EC, Tzankov A, Ackermann C, Membrez-Antonioli V, Zürrer-Härdi U, Caspar CB, Deuster S, Senn M, Winterhalder R, Rochlitz C. Mamot C, et al. Sci Rep. 2023 Mar 6;13(1):3705. doi: 10.1038/s41598-023-30950-z. Sci Rep. 2023. PMID: 36879012 Free PMC article. Clinical Trial.
Decision-Making among Experts in Advanced Hodgkin Lymphoma.
Hitz F, Lang N, Mey U, Mingrone W, Moccia A, Taverna C, Novak U, Stenner F, Schmidt A, Mamot C, Fischer N, Putora PM. Hitz F, et al. Among authors: mamot c. Oncology. 2023;101(3):159-165. doi: 10.1159/000526360. Epub 2022 Sep 27. Oncology. 2023. PMID: 36103806 Free article.
Integration of Baseline Metabolic Parameters and Mutational Profiles Predicts Long-Term Response to First-Line Therapy in DLBCL Patients: A Post Hoc Analysis of the SAKK38/07 Study.
Genta S, Ghilardi G, Cascione L, Juskevicius D, Tzankov A, Schär S, Milan L, Pirosa MC, Esposito F, Ruberto T, Giovanella L, Hayoz S, Mamot C, Dirnhofer S, Zucca E, Ceriani L. Genta S, et al. Among authors: mamot c. Cancers (Basel). 2022 Feb 17;14(4):1018. doi: 10.3390/cancers14041018. Cancers (Basel). 2022. PMID: 35205765 Free PMC article.
Targeting immunoliposomes to EGFR-positive glioblastoma.
Kasenda B, König D, Manni M, Ritschard R, Duthaler U, Bartoszek E, Bärenwaldt A, Deuster S, Hutter G, Cordier D, Mariani L, Hench J, Frank S, Krähenbühl S, Zippelius A, Rochlitz C, Mamot C, Wicki A, Läubli H. Kasenda B, et al. Among authors: mamot c. ESMO Open. 2022 Feb;7(1):100365. doi: 10.1016/j.esmoop.2021.100365. Epub 2022 Jan 5. ESMO Open. 2022. PMID: 34998092 Free PMC article. Clinical Trial.
Generation and validation of a PET radiomics model that predicts survival in diffuse large B cell lymphoma treated with R-CHOP14: A SAKK 38/07 trial post-hoc analysis.
Ceriani L, Milan L, Cascione L, Gritti G, Dalmasso F, Esposito F, Pirosa MC, Schär S, Bruno A, Dirnhofer S, Giovanella L, Hayoz S, Mamot C, Rambaldi A, Chauvie S, Zucca E. Ceriani L, et al. Among authors: mamot c. Hematol Oncol. 2022 Feb;40(1):11-21. doi: 10.1002/hon.2935. Epub 2021 Oct 29. Hematol Oncol. 2022. PMID: 34714558
The addition of deep hyperthermia to gemcitabine-based chemoradiation may achieve enhanced survival in unresectable locally advanced adenocarcinoma of the pancreas.
Rogers SJ, Datta NR, Puric E, Timm O, Marder D, Khan S, Mamot C, Knuchel J, Siebenhüner A, Pestalozzi B, Guckenberger M, Bodis S, Riesterer O. Rogers SJ, et al. Among authors: mamot c. Clin Transl Radiat Oncol. 2021 Jan 25;27:109-113. doi: 10.1016/j.ctro.2021.01.008. eCollection 2021 Mar. Clin Transl Radiat Oncol. 2021. PMID: 33598571 Free PMC article.
Prognostic models integrating quantitative parameters from baseline and interim positron emission computed tomography in patients with diffuse large B-cell lymphoma: post-hoc analysis from the SAKK38/07 clinical trial.
Zucca E, Cascione L, Ruberto T, Facchinelli D, Schär S, Hayoz S, Dirnhofer S, Giovanella L, Bargetzi M, Mamot C, Ceriani L. Zucca E, et al. Among authors: mamot c. Hematol Oncol. 2020 Dec;38(5):715-725. doi: 10.1002/hon.2805. Epub 2020 Oct 4. Hematol Oncol. 2020. PMID: 32947651
48 results